Core Viewpoint - Geopolitical events, judicial rulings, new law legislation, and policy changes are significantly impacting stock movements across various industrial sectors [1] Group 1 - Geopolitical events are influencing market dynamics and causing volatility in stock prices [1] - Judicial rulings are leading to substantial shifts in investor sentiment and stock performance [1] - New law legislation is creating opportunities and challenges for different industries, affecting their market valuations [1] - Policy changes are reshaping the competitive landscape, prompting companies to adjust their strategies [1]

Core Viewpoint - AbbVie has lowered its annual profit forecast due to a $2.7 billion charge related to in-process research and development (IPR&D) expenses in Q3, impacting its adjusted earnings per share (EPS) expectations significantly [1][2]. Financial Performance - AbbVie now expects full-year adjusted EPS to be between $10.38 and $10.58, down from the previous range of $11.88 to $12.08, with analysts initially expecting $12.02 [2][3]. - The forecast for Q3 adjusted EPS is projected to be between $1.74 and $1.78, which is substantially lower than the analysts' estimate of $3.27 [4]. Research and Development - The IPR&D expenses may arise from collaborations, licensing deals, or asset purchases, but the company did not specify the exact nature of these expenses [2]. - AbbVie has indicated that the results for the quarter ending September 30 are not finalized and may differ from preliminary estimates [3]. Strategic Developments - AbbVie has initiated the construction of a new active pharmaceutical ingredient manufacturing plant in North Chicago, Illinois, with an investment of $195 million, expected to be operational by 2027 [4]. - The company is focusing on newer immunology drugs, Skyrizi and Rinvoq, to counteract declining sales from its arthritis treatment Humira, which is facing biosimilar competition in the U.S. [5]. Acquisitions and Investments - AbbVie has invested over $20 billion in acquisitions since the onset of biosimilar competition for Humira to strengthen its product pipeline [5].

Core Insights - AbbVie expects to incur a $2.7 billion charge in its third-quarter earnings due to in-process research and development (IPR&D) expenses [1] Financial Impact - The $2.7 billion charge is specifically related to IPR&D expenses, indicating significant investment in ongoing research projects [1]

FORM 8-K Filing Information This section provides administrative details for the Form 8-K filing, including registrant identification and event date [Registrant and Filing Details](index=1&type=section&id=Registrant%20and%20Filing%20Details) This section provides basic identification details for the Form 8-K filing, including the registrant's name, address, and the date of the earliest event reported - Registrant is ABBVIE INC., located at 1 North Waukegan Road, North Chicago, Illinois[1](index=1&type=chunk)[2](index=2&type=chunk) - The date of the earliest event reported is October 3, 2025[1](index=1&type=chunk) [Securities Registered](index=1&type=section&id=Securities%20Registered) This section lists the classes of securities registered by AbbVie Inc. pursuant to Section 12(b) of the Act, including common stock and various senior notes, along with their trading symbols and the exchanges on which they are registered Securities Registered | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.01 Par Value | ABBV | New York Stock Exchange, NYSE Texas | | 0.750% Senior Notes due 2027 | ABBV27 | New York Stock Exchange | | 2.125% Senior Notes due 2028 | ABBV28 | New York Stock Exchange | | 2.625% Senior Notes due 2028 | ABBV28B | New York Stock Exchange | | 2.125% Senior Notes due 2029 | ABBV29 | New York Stock Exchange | | 1.250% Senior Notes due 2031 | ABBV31 | New York Stock Exchange | [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) This section outlines AbbVie's preliminary financial estimates for Q3 2025, highlighting a significant pre-tax acquired IPR&D and milestones expense [Third Quarter 2025 Preliminary Financial Estimates](index=2&type=section&id=Third%20Quarter%202025%20Preliminary%20Financial%20Estimates) AbbVie expects its Q3 2025 GAAP and adjusted non-GAAP earnings to be significantly impacted by a $2.7 billion pre-tax acquired IPR&D and milestones expense, resulting in an unfavorable $1.50 impact per share - Q3 2025 GAAP and adjusted non-GAAP earnings are expected to include **$2.7 billion pre-tax acquired IPR&D and milestones expense**[5](index=5&type=chunk) - This expense represents an unfavorable impact of **$1.50** to both GAAP and adjusted non-GAAP diluted earnings per share[5](index=5&type=chunk) - Results for the quarter ended September 30, 2025, are preliminary and subject to financial statement closing procedures[5](index=5&type=chunk) [Updated Earnings Per Share Guidance](index=2&type=section&id=Updated%20Earnings%20Per%20Share%20Guidance) The company has updated its full-year and third-quarter 2025 adjusted diluted EPS guidance to include the impact of the acquired IPR&D and milestones expense, which was previously excluded from forecasts due to its uncertain nature - AbbVie does not typically forecast acquired IPR&D and milestones expense due to uncertainty in occurrence and timing[6](index=6&type=chunk) Updated Adjusted Diluted EPS Guidance (including Q3 2025 IPR&D expense) | Period | Adjusted Diluted EPS Guidance Range | | :----- | :---------------------------------- | | Full-year 2025 | $10.38 - $10.58 | | Third Quarter 2025 | $1.74 - $1.78 | - Guidance for 2025, including the estimated acquired IPR&D and milestones expense, is furnished as Exhibit 99.1[7](index=7&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) This section provides a disclaimer regarding the inherent risks and uncertainties associated with forward-looking statements in the report [Disclaimer on Future Performance](index=2&type=section&id=Disclaimer%20on%20Future%20Performance) This standard disclosure warns that some statements in the report are forward-looking and subject to various risks and uncertainties, including intellectual property challenges, competition, R&D difficulties, litigation, regulatory changes, and macroeconomic factors, which could cause actual results to differ materially - Forward-looking statements are identified by words like 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions[9](index=9&type=chunk) - Such statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied[9](index=9&type=chunk) - Risks include challenges to intellectual property, competition, R&D difficulties, adverse litigation, regulatory changes, and global macroeconomic factors[9](index=9&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the financial statements and exhibits included in the Form 8-K filing [Exhibits Filed](index=2&type=section&id=Exhibits%20Filed) This item lists the exhibits accompanying the Form 8-K, specifically Exhibit 99.1, which provides detailed guidance including the impact of acquired IPR&D and milestones expense, and Exhibit 104 for the Inline XBRL cover page Exhibits | Exhibit No. | Exhibit Description | | :---------- | :------------------ | | 99.1 | Guidance including the impact of acquired IPR&D and milestones expense | | 104 | The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) | [SIGNATURE](index=4&type=section&id=SIGNATURE) This section formally concludes the Form 8-K filing, indicating due authorization and signature [Report Authorization](index=4&type=section&id=Report%20Authorization) This section formally concludes the Form 8-K filing, indicating that the registrant has duly authorized and signed the report - The report was signed on October 3, 2025, by Scott T. Reents, Executive Vice President and Chief Financial Officer of ABBVIE INC[14](index=14&type=chunk)

Group 1 - AbbVie has experienced strong performance recently, with a thriving commercial business and successful late-stage pipeline developments [2] - The legal team at AbbVie has secured long-term exclusivity for Rinvoq, enhancing its market position [2] Group 2 - The Growth Stock Forum offers a model portfolio of 15-20 stocks, a top picks list of up to 10 stocks expected to perform well, and trading ideas for both short-term and medium-term strategies [2]

Core Insights - AbbVie has shown strong performance recently, with a thriving commercial business and successful late-stage pipeline developments [2] Group 1: Company Performance - AbbVie's commercial business is performing well, indicating robust sales and market presence [2] - The company has achieved significant late-stage wins and approvals in its pipeline, suggesting a promising future for its product offerings [2] Group 2: Legal and Competitive Position - AbbVie's legal team has secured long-term exclusivity for Rinvoq, enhancing its competitive position in the market [2]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] - A specific company is highlighted as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI technologies [3][7][8] Investment Landscape - Wall Street is investing hundreds of billions into AI, but there is a looming question regarding the energy supply needed to sustain this growth [2] - AI data centers consume vast amounts of energy, comparable to that of small cities, indicating a significant strain on global power grids [2] - The company in focus is positioned to benefit from the surge in demand for electricity driven by AI advancements, making it a unique investment opportunity [3][6] Company Profile - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend due to tariffs [5][6] - It possesses critical nuclear energy infrastructure assets, making it integral to America's future power strategy [7] - The company is noted for its ability to execute large-scale engineering, procurement, and construction projects across various energy sectors, including oil, gas, and renewables [7] Financial Position - The company is completely debt-free and has a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also holds a substantial equity stake in another AI-related company, providing indirect exposure to multiple growth engines in the AI sector [9] Market Sentiment - There is a growing interest from hedge funds in this company, which is considered undervalued and off-the-radar, trading at less than seven times earnings [10][11] - The company is recognized for delivering real cash flows and owning critical infrastructure, making it a compelling investment choice in the context of the AI and energy sectors [11][12]

Core Insights - AbbVie stock (NYSE: ABBV) experienced an 11% rally in one week, primarily due to Pfizer's agreement to lower drug prices for Medicaid and a White House decision to grant a three-year exemption from 100% import tariffs, which is viewed positively for the pharmaceutical sector [3] - AbbVie has seen a 15.3% increase in stock price over the past month, prompting comparisons with peers to assess its performance, valuation, and financial metrics [6] Company Overview - AbbVie develops pharmaceuticals for autoimmune diseases, plaque psoriasis, pancreatic insufficiency, and hypothyroidism, focusing on innovative drug development and manufacturing in the United States [4] Performance Metrics - AbbVie's operating margin stands at 23.5%, which is lower than competitors like Eli Lilly (LLY) at 43.0% [8] - AbbVie's revenue growth over the past year is 6.1%, which is moderate and surpasses Merck (MRK), Gilead (GILD), and Bristol-Myers Squibb (BMY), but is below LLY and Amgen (AMGN) [8] - Over the last year, AbbVie's stock has increased by 28.5% and is currently trading at a price-to-earnings (PE) ratio of 114.8, although competitors like GILD have shown higher returns [8]

About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X ( ...

Core Viewpoint - AbbVie is facing a cautious outlook following a downgrade by HSBC, yet the company is actively investing in its operations to enhance its manufacturing and research capabilities in response to growing global demand for its products [1][2]. Company Developments - AbbVie has initiated a $70 million expansion at its Bioresearch Center in Worcester, Massachusetts, as part of a broader $10 billion investment in U.S. operations [2]. - The expansion will include new manufacturing areas and a three-story building for laboratories, warehouse, and office spaces, facilitating the transfer of select oncology products from Europe to the U.S. [3]. Stock Performance - AbbVie's stock is currently trading at $244.38, reflecting a 5.55% increase, with a market capitalization of approximately $431.7 billion and a trading volume of 11.28 million shares [4]. - The stock has shown significant growth over the past year, with a lowest price of $163.81 and a highest price of $244.81 today [4].